We develop novel and differentiated oral small molecule therapies to patients suffering from diseases with significant unmet medical need.
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.
We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, we are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
Two royalty bearing collaborations with AbbVie and Boehringer Ingelheim
Two innovative clinical programs: NATIVE and IMPROVES
Pre-clinical pipeline in oncology and fibrosis
State of the art R&D capabilities inherited from Abbott, Solvay, Fournier
Inventiva was co-founded by Frédéric Cren, Chairman and CEO and Pierre Broqua, Chief Scientific Officer, in Dijon in 2012.
Both have strong expertise within the areas of research, development and strategy and held senior research and executive positions at both Fournier and Solvay prior to founding Inventiva.
Frédéric Cren, Inventiva CO-Founder and CEO, for Société Générale
Research Areas & Pipeline
With many potential new therapies currently in clinical trials, our goal is to be the industry leader in development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators.
Lanifibranor, our lead product candidate, is an anti-fibrotic treatment acting on the three PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the metabolic, inflammatory and fibrotic processes. We are investigating lanifibranor for the treatment of NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States.
We are developing a second clinical program with odiparcil for the treatment of patients with mucopolysaccaridosis type VI (MPS), a rare and severe genetic disease. Odiparcil also has the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome).
Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott.
The company owns a chemical library of over 240,000 molecules, 60% of which are proprietary, as well as integrated biology, chemistry, ADME and pharmacology platforms.